Skip to main content

and
  1. Article

    Open Access

    Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis

    Hussein Awada, Arda Durmaz, Tariq Kewan, Fauzia Ullah, Danai Dima, Hassan Awada in Leukemia (2024)

  2. Article

    Open Access

    Clonal hematopoiesis–derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders

    Therapy-related myeloid neoplasms (tMN) are complications of cytotoxic therapies. Risk of tMN is high in recipients of autologous hematopoietic stem cell transplantation (aHSCT). Acquisition of genomic mutatio...

    Hussein Awada, Carmelo Gurnari, Valeria Visconte, Arda Durmaz in Leukemia (2024)

  3. Article

    Open Access

    Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting

    PHF6 mutations (PHF6MT) are identified in various myeloid neoplasms (MN). However, little is known about the precise function and consequences of PHF6 in MN. Here we show three main findings in our comprehensive ...

    Yasuo Kubota, **aorong Gu, Laila Terkawi, Juraj Bodo in Nature Communications (2024)

  4. Article

    Open Access

    Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia

    Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari in Nature Communications (2024)

  5. Article

    Open Access

    Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets

    Complete or partial deletions of chromosome 7 (-7/del7q) belong to the most frequent chromosomal abnormalities in myeloid neoplasm (MN) and are associated with a poor prognosis. The disease biology of -7/del7q...

    Minako Mori, Yasuo Kubota, Arda Durmaz, Carmelo Gurnari, Charnise Goodings in Leukemia (2023)

  6. Article

    Open Access

    Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia

    TP53 mutations (TP53MT) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly le...

    Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz in Journal of Hematology & Oncology (2023)

  7. Article

    Open Access

    Molecular patterns identify distinct subclasses of myeloid neoplasia

    Genomic mutations drive the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia. While morphological and clinical features have dominated the classical criteria for diagnosis and classificatio...

    Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari in Nature Communications (2023)

  8. No Access

    Article

    Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations

    Hassan Awada, Cassandra M. Kerr, Arda Durmaz, Vera Adema, Carmelo Gurnari in Leukemia (2021)

  9. Article

    Open Access

    Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients

    Patient-derived xenografts established from human cancers are important tools for investigating novel anti-cancer therapies. Establishing PDXs requires a significant investment and many PDXs may be used infreq...

    Lindsey Abel, Arda Durmaz, Rong Hu, Colin Longhurst in Journal of Translational Medicine (2021)

  10. Article

    Open Access

    Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases

    Non-small cell lung cancer (NSCLC) brain metastasis cell lines and in vivo models are not widely accessible. Herein we report on a direct-from patient-derived xenograft (PDX) model system of NSCLC brain metast...

    Andrew M. Baschnagel, Saakshi Kaushik, Arda Durmaz, Steve Goldstein in Scientific Reports (2021)

  11. Article

    Open Access

    Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

    Despite high initial efficacy, targeted therapies eventually fail in advanced cancers, as tumors develop resistance and relapse. In contrast to the substantial body of research on the molecular mechanisms of r...

    Robert Vander Velde, Nara Yoon, Viktoriya Marusyk, Arda Durmaz in Nature Communications (2020)